The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
Authors:
- Pauline AaltenPAPauline Aalten
- Inez Hgb RamakersIRInez Hgb Ramakers
- Geert Jan BiesselsGBGeert Jan Biessels
- Peter Paul de DeynPDPeter Paul de Deyn
- Huiberdina L KoekHuiberdina L Koek
- Marcel GM OldeRikkertMOMarcel GM OldeRikkert
- Ania M OleksikAOAnia M Oleksik
- Edo RichardEREdo Richard
- Lieke L SmitsLSLieke L Smits
- John C van SwietenJSJohn C van Swieten
- Laura K TeuneLTLaura K Teune
- Aad van der LugtALAad van der Lugt
Open Access
- 31 December 2014
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 1-8
Abstract
The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical data and biomaterials from patients suffering from chronic diseases (so called “Pearls”) are collected according to harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis, differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer’s disease. The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as baseline descriptive variables, including their biomarker profile. The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients, respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%). The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and biomaterials of more than 1000 patients with cognitive impairments. The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset.Keywords
This publication has 33 references indexed in Scilit:
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Revising the definition of Alzheimer's disease: a new lexiconThe Lancet Neurology, 2010
- Alzheimer's disease: progress in predictionThe Lancet Neurology, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Is MCI really just early dementia? A systematic review of conversion studiesInternational Psychogeriatrics, 2004
- Frontotemporal lobar degenerationNeurology, 1998
- Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)Neurology, 1996